A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age20-85
SponsorFujian Cancer Hospital
About this trial
This study aims to help to screen out appropriate cases for consolidation therapy and more intensive follow up.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
patients confirmed as cervical cancer by biopsies and treated with radiotherapy were initially enrolled
Disqualifiers
(1) patients treated with surgery. (2) patient received incomplete treatment somewhere else. (3) patients with cancer history. (4) patients with pelvic surgery history. (5) patients without complete pre-treatment medical information. (6) patients with unfinished radical radiotherapy. (7) patients suffered from metastasis within 3 months after radiotherapy. (8) patients without complete 1-year follow-up materials
Trial population
cervical cancer patients recevied definitive radiotherapy.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT)
RadiationRadical RT consisted of external pelvic beam radiotherapy (EBRT) and individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT).Cisplatin-based concurrent chemoradiotherapy (CCRT) was recommended for CC patients unless for economic status, age consideration and patients' desires.
Treatment groups
500 Participants
are divided into 1 treatment groupGroup A: cervical cancer patients with radiotherapy1 intervention
Trial outcomes
Primary outcomes
1
Early distant metastases
Early distant metastasis defines as metastasis occurrence between 3 -12 months after radiotherapy.
Time frame
3-12monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: